Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02963506 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis
A Phase 2 study, sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 2
- Development phase
- 303
- Enrollment target
NCT02963506 is a Phase 2 study that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 303 participants.
The verdict
NCT02963506, a Phase 2 study, has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 303 participants
- Enrollment target
Study Summary
This is a study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis (AS).
Interventions
- OTHER Placebo
- DRUG Bimekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02963506
The ClinicalTrials.gov registry entry for NCT02963506 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02963506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02963506 about?
NCT02963506 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis". This is a study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis (AS).
What is the current status of trial NCT02963506?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 303 participants. The study started on 2016-10. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02963506?
The interventions under investigation include: Placebo (OTHER), Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT02963506?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.